The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia [1]

British Journal of Haematology

Volumn 132, Issue 2, 2006, Pages 244-245

  Cheung, Betty ^a   Radia, Deepti ^a   Pantelidis, Panagiotis ^a   Yadegarfar, Ghasem ^a   Harrison, Claire ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Essential thrombocythaemia; JAK2; Thrombosis

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2; JAK2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; STATISTICAL ANALYSIS; THROMBOCYTHEMIA; THROMBOSIS; CHILD; GENETICS; METABOLISM; MIDDLE AGED; POINT MUTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HEMOGLOBINS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; POINT MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 33644826144     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05858.x     Document Type: Letter

References (6)

1. Antonioli E. Guglielmelli P. Pancrazzi A. Bogani C. Verruci M. Ponziani V. Longo G. Bosi A. Vannucchi A.M. 2005 Clinical implications of the JAK2 V617F mutation in essential thrombocythaemia Leukaemia 19 1847 1849
2. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. Vassilious G.S. Bench A.J. Boyd E.M. Curtin N. Scott M.A. Erber W.N. Green A.R. 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders The Lancet 365 1054 1061
3. James C. Ugo V. Le Couedic J.P. Staerck J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker W. 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144 1148
4. Jones A.V. Kreil S. Zoi K. Waghorn K. Curtis C. Zhang L. Score J. Seear R. Chase A.J. Grand F.H. White H. Zoi C. Loukopoulos D. Terpos E. Vervessou E.C. Schultheis B. Emig M. Ernst T. Lengfelder E. Hehlmann R. Hochhaus A. Oscier D. Silver R.T. Reiter A. Cross N.C. 2005 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood 106 2162 2168
5. Kralovics R. Passamonti F. Buser A.S. Teo S.S. Tiedt R. Passweg J.R. Tichelli A. Cazzola M. Skoda R.C. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders New England Journal of Medicine 352 1779 1790
6. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. 2005 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387 397